Parameter
| Biomarker | PD-L1 | Full name | Programmed death-ligand 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | To predict immunotherapy response and prognosis | ||
| Disease | Hepatocellular Carcinoma (HCC) - | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Tumor tissue /CTCs (IHC, flow cytometry) | ||
| Pathobiological Mechanisms | Tumor cell surface molecules, combined with PD-1, inhibit T cell activation and mediate immune escape | ||||
| Clinical Availability Status | Study validation: The correlation between PD-L1 expression in tumor tissue and the efficacy of ICIs is not clear | ||||
| Notes and Dynamics | PD-L1+CTCs can more dynamically reflect the response to immunotherapy and is a potential predictor | ||||